During the COVID-19 pandemic, several pharma companies moved so fast to develop vaccines that the amount of time between the sequencing of the virus to the introduction of the first three vaccines was less than a year. It was a feat that was facilitated by unprecedented collaboration between the government and private industry, as well as efficient research and development processes—all of which could be leveraged in the future to improve vaccine development.

The processes that enabled that ultrafast clinical development of COVID-19 vaccines included real-time data sharing among academic research groups and companies; the standardization of reagents and models used in preclinical testing; a streamlined approach to clinical trials and manufacturing, and more. All of those practices could be embraced to improve and accelerate vaccine development going forward.

This Fierce webinar will include input from vaccine R&D professionals, including experts in clinical trial design, regulatory affairs and manufacturing. They will draw upon their own experiences in vaccine development to offer tips for incorporating elements of the successful COVID-19 vaccine rollout into future vaccine programs.

Topics include:

  • Embracing new technology to improve collaboration across research and development
  • New ideas for driving efficiency in manufacturing to compress delivery timelines
  • Combating vaccine hesitancy among consumers: What works and what doesn’t

Featured Speaker

Veda K. Walcott, MT, MBA

Vice President, Global Regulatory Affairs and Compliance

Ms. Walcott has over 19 years of experience in the Biopharmaceutical industry. Today, she is responsible for corporate quality system policy, compliance and regulatory affairs support for a broad product portfolio across Catalent’s global network of 40+ facilities. She previously served as Vice President of Quality and Regulatory Affairs for Catalent Indiana, LLC (formerly Cook Pharmica) from 2007 to 2018 and was responsible for oversight of quality assurance, analytical services, validation and regulatory affairs for the state-of-the-art Bloomington, Indiana CDMO facility providing development, mammalian cell culture, formulation, parenteral filling, inspection, and packaging capabilities. She has extensive experience in managing Health Authority inspections, supporting design and qualification of major expansions, and implementing Quality Systems. She is also passionate about mentorship and is an active member of the Catalent Women’s Network. Veda holds a bachelor’s degree from Indiana State University in Clinical Laboratory Science, as well as a MBA from Indiana Wesleyan University.

Paul Turner, MD

VP & Global Head of Medical Strategy for Infectious Diseases & Vaccines

Paul provides medical, clinical and scientific advisory expertise in Infectious Diseases and Vaccines (IDV) & for COVID-19 treatment and vaccine trials. Provides senior oversight in all aspects of Medical Science involvement on customer projects including early engagement work. Develop medically sound delivery strategies for large, complex, multi-region studies or programs, including mega studies and portfolio management, in partnership with other stakeholders.

Date:  Wednesday, August 11, 2021
Time:  11am ET / 8am PT
Duration:  1 Hour

Register now for this webinar